Equilibrative Nucleoside Transporters 1 and 4: Which One Is a Better Target for Cardioprotection Against...

Area of Science:

• Cardiovascular Research
• Pharmacology
• Molecular Biology

Background:

• Adenosine and its agonists show cardioprotective effects but have limited therapeutic use in ischemic heart disease due to systemic side effects.
• Equilibrative nucleoside transporter (ENT) inhibitors are explored as an alternative strategy to enhance endogenous adenosine's cardioprotective actions.

Purpose of the Study:

• To evaluate the potential of ENT inhibitors, particularly ENT4 inhibitors, as a therapeutic strategy for ischemic heart disease.
• To compare the potential benefits and limitations of ENT1 and ENT4 inhibition in the context of cardiac protection and systemic effects.

Main Methods:

• The study reviews existing literature on adenosine, ENT1, and ENT4 transporters in the context of cardiac physiology and ischemic heart disease.
• It analyzes the proposed mechanisms of action for ENT1 and ENT4 inhibitors regarding adenosine transport and extracellular levels.

Main Results:

• ENT1 inhibitors potentiate endogenous adenosine's cardioprotective effects by reducing adenosine uptake but may cause long-term adverse effects and interact with nucleoside analogs.
• ENT4 inhibitors are proposed to selectively increase extracellular adenosine in ischemic tissues, potentially avoiding systemic side effects and interactions with chemotherapy agents.

Conclusions:

• ENT4 inhibitors represent a promising therapeutic avenue for ischemic heart disease, offering targeted action with a potentially improved safety profile compared to ENT1 inhibitors.
• Further research into specific ENT4 inhibitors is warranted to explore their full therapeutic potential in managing ischemic heart disease.